Disease · MONDO_0044212

chronic idiopathic urticaria

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. chronic idiopathic urticaria. Diseases, record MONDO_0044212. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0044212

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: chronic idiopathic urticaria; Open Targets
Open Targets ID: MONDO_0044212; Open Targets
Other names: idiopathic urticaria, chronic; Open Targets
Disease Ontology: DOID:0080749; Disease Ontology
Highest stage of its drugs: Phase 3, for 10 of its 24 drugs, from ClinicalTrials.gov and TTD; Open Targets

Drugs24

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
OMALIZUMAB	CHEMBL1201589	Antibody	Phase 3	ClinicalTrials.gov	20	18	18	Drugs and targets
LIGELIZUMAB	CHEMBL2109457	Antibody	Phase 3	ClinicalTrials.gov and TTD	10	8	8	Drugs and targets
REMIBRUTINIB	CHEMBL4483575	Small molecule	Phase 3	ClinicalTrials.gov	7	5	5	Drugs and targets
BARZOLVOLIMAB	CHEMBL5095266	Antibody	Phase 3	ClinicalTrials.gov	5	4	4	Drugs and targets
LEVOCETIRIZINE	CHEMBL1201191	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
DUPILUMAB	CHEMBL2108675	Antibody	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
DESLORATADINE	CHEMBL1172	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
RUPATADINE	CHEMBL91397	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
BILASTINE	CHEMBL1742423	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
METHOTREXATE	CHEMBL34259	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 24

See all 24 drugs

Targets16

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
HRH1	Histamine H1 receptor	4	Histamine H1 receptor antagonist; Histamine H1 receptor inverse agonist	Phase 3	https://conductscience.org/library/genes/3269	Drugs and targets
BTK	Tyrosine-protein kinase BTK	3	Tyrosine-protein kinase BTK inhibitor	Phase 2	https://conductscience.org/library/genes/695	Drugs and targets
IGHE	Immunoglobulin heavy constant epsilon	2	Ig epsilon chain C region inhibitor	Phase 3	https://conductscience.org/library/genes/3497	Drugs and targets
CNR1	Cannabinoid receptor 1	1	Cannabinoid CB1 receptor negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/1268	Drugs and targets
DHFR	Dihydrofolate reductase	1	Dihydrofolate reductase inhibitor	Phase 3	https://conductscience.org/library/genes/1719	Drugs and targets
IL1B	Interleukin-1 beta	1	Interleukin-1 beta inhibitor	Phase 2	https://conductscience.org/library/genes/3553	Drugs and targets
IL4R	Interleukin-4 receptor subunit alpha	1	Interleukin-4 receptor subunit alpha antagonist	Phase 3	https://conductscience.org/library/genes/3566	Drugs and targets
IL5	Interleukin-5	1	Interleukin-5 inhibitor	Early phase 1	https://conductscience.org/library/genes/3567	Drugs and targets
IL5RA	Interleukin-5 receptor subunit alpha	1	Interleukin-5 receptor subunit alpha inhibitor	Phase 2	https://conductscience.org/library/genes/3568	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	1	Stem cell growth factor receptor inhibitor	Phase 1/2	https://conductscience.org/library/genes/3815	Drugs and targets

1 to 10 of 16

See all 16 targets

Trials55

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03580356	A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.	Phase 3	1,078	2024-03-25	Chronic Spontaneous Urticaria	LIGELIZUMAB, OMALIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT03580369	A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines	Phase 3	1,072	2022-12-30	Chronic Spontaneous Urticaria	LIGELIZUMAB, OMALIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT04210843	Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab	Phase 3	1,033	2023-07-13	Chronic Spontaneous Urticaria	LIGELIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT04426890	To Compare Efficacy and Safety of CT-P39 and EU-approved Xolair in Patients With Chronic Spontaneous Urticaria	Phase 3	634	2025-07-29	Chronic Spontaneous Urticaria	OMALIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT05030311	A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines	Phase 3	470	2024-12-02	Chronic Spontaneous Urticaria	REMIBRUTINIB	Open Targets' reading of its record	ClinicalTrials.gov
NCT05032157	A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines	Phase 3	455	2024-11-01	Chronic Spontaneous Urticaria	REMIBRUTINIB	Open Targets' reading of its record	ClinicalTrials.gov
NCT03328897	Study of Efficacy and Safety of Xolair® (Omalizumab) in Chinese Patients With Chronic Spontaneous Urticaria	Phase 3	418	2020-11-04	Chronic Spontaneous Urticaria	OMALIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT04180488	Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)	Phase 3	397	2025-08-20	Chronic Spontaneous Urticaria	DUPILUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT02477332	Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU	Phase 2	382	2018-09-14	Chronic Spontaneous Urticaria	LIGELIZUMAB, OMALIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT01264939	A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists	Phase 3	336	2013-11-26	Chronic Idiopathic Urticaria	OMALIZUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 55

See all 55 trials

Comparisons in its trials18

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
LOU064 25mg b.i.d. vs Placebo: Number of Patients Who Achieved Disease Activity Control (UAS7 ≤6)	154 of 309	38 of 153	462	NCT05030311	Trial comparisons
LOU064 25mg b.i.d. vs Placebo: Number of Patients With Early Onset of Disease Control (UAS7 ≤ 6 at Week 2)	104 of 309	5 of 153	462	NCT05030311	Trial comparisons
LOU064 25mg b.i.d. vs Placebo: Number of Patients Who Achieved Complete Absence of Hives and Itch (UAS7 = 0)	96 of 309	16 of 153	462	NCT05030311	Trial comparisons
LOU064 25mg b.i.d. vs Placebo: Number of Patients Who Achieved DLQI = 0 - 1	120 of 308	34 of 153	461	NCT05030311	Trial comparisons
QGE031 240 mg q4w (TEAE) vs QGE031 240 mg q4w (Non-TEAE): deaths from any cause	1 of 226	0 of 226	452	NCT02649218	Trial comparisons
QGE031 240 mg q4w (TEAE) vs QGE031 240 mg q4w (Non-TEAE): serious adverse events	15 of 226	6 of 226	452	NCT02649218	Trial comparisons
LOU064 25 mg b.i.d. vs Placebo: Number of Participants Who Achieved Early Onset of Disease Activity Control (UAS7 =< 6) at Week 2	89 of 297	9 of 153	450	NCT05032157	Trial comparisons
LOU064 25 mg b.i.d. vs Placebo: Number of Participants Who Achieved Dermatology Life Quality Index (DLQI) = 0-1 at Week 12	106 of 297	28 of 153	450	NCT05032157	Trial comparisons
LOU064 25 mg b.i.d. vs Placebo: Number of Participants Who Achieved Complete Absence of Hives and Itch (UAS7 = 0) at Week 12	83 of 297	10 of 153	450	NCT05032157	Trial comparisons
LOU064 25 mg b.i.d. vs Placebo: Number of Participants Who Achieved Disease Activity Control (UAS7 =< 6) at Week 12	139 of 297	30 of 153	450	NCT05032157	Trial comparisons

1 to 10 of 18

See all 18 comparisons in its trials

Papers from its trials31

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
19860762	RESULT	1	PubMed
17478385	RESULT	1	PubMed
42297099	DERIVED	2	PubMed
41847564	DERIVED	1	PubMed
41747871	DERIVED	1	PubMed
41706458	DERIVED	1	PubMed
41326897	DERIVED	1	PubMed
41272364	DERIVED	1	PubMed
40266575	DERIVED	1	PubMed
40043237	DERIVED	2	PubMed

1 to 10 of 31

See all 31 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0044212

GET https://conductscience.org/api/diseases/v1/MONDO_0044212/drugs?page=2

API reference For AI assistants